Last reviewed · How we verify
Dbcamp — Competitive Intelligence Brief
phase 2
bucladesine
Hematology
Small molecule
Live · refreshed every 30 min
Target snapshot
Dbcamp (BUCLADESINE). Dbcamp works by increasing levels of cyclic AMP (cAMP) in the body, which helps to relax smooth muscle and improve blood flow.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Dbcamp TARGET | BUCLADESINE | phase 2 | bucladesine |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (bucladesine class)
- · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Dbcamp CI watch — RSS
- Dbcamp CI watch — Atom
- Dbcamp CI watch — JSON
- Dbcamp alone — RSS
- Whole bucladesine class — RSS
Cite this brief
Drug Landscape (2026). Dbcamp — Competitive Intelligence Brief. https://druglandscape.com/ci/bucladesine. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing